In the BioHarmony Drug Report Database

"Preview" Icon

Temsirolimus

Torisel (temsirolimus) is a small molecule pharmaceutical. Temsirolimus was first approved as Torisel on 2007-05-30. It is used to treat renal cell carcinoma in the USA. It has been approved in Europe to treat mantle-cell lymphoma and renal cell carcinoma. The pharmaceutical is active against serine/threonine-protein kinase mTOR. Torisel’s patents are valid until 2032-05-10 (FDA).

 

Trade Name

 

Torisel
 

Common Name

 

temsirolimus
 

ChEMBL ID

 

CHEMBL1201182
 

Indication

 

mantle-cell lymphoma, renal cell carcinoma
 

Drug Class

 

Immunosuppressives: immunosuppressant, rapamycin derivatives

Image (chem structure or protein)

Temsirolimus structure rendering